Literature DB >> 29625100

National Comparison of Hospital Performances in Lung Cancer Surgery: The Role of Case Mix Adjustment.

Naomi Beck1, Fieke Hoeijmakers2, Esmee M van der Willik3, David J Heineman4, Jerry Braun5, Rob A E M Tollenaar2, Wilhelmina H Schreurs6, Michel W J M Wouters7.   

Abstract

BACKGROUND: When comparing hospitals on outcome indicators, proper adjustment for case mix (a combination of patient and disease characteristics) is indispensable. This study examines the need for case mix adjustment in evaluating hospital outcomes for non-small cell lung cancer surgery.
METHODS: Data from the Dutch Lung Cancer Audit for Surgery were used to validate factors associated with postoperative 30-day mortality and complicated course with multivariable logistic regression models. Between-hospital variation in case mix was studied by calculating medians and interquartile ranges for separate factors on the hospital level and the "expected" outcomes per hospital as a composite measure.
RESULTS: A total of 8,040 patients, distributed over 51 Dutch hospitals, were included for analysis. Mean observed postoperative mortality and complicated course were 2.2% and 13.6%, respectively. Age, American Society of Anesthesiologists classification, Eastern Cooperative Oncology Group performance score, lung function, extent of resection, tumor stage, and postoperative histopathologic findings were individual significant predictors for both outcomes of postoperative mortality and complicated course. A considerable variation of these case mix factors among hospital populations was observed, with the expected mortality and complicated course per hospital ranging from 1.4% to 3.2% and from 11.5% to 17.1%, respectively.
CONCLUSIONS: The between-hospital variation in case mix of patients undergoing surgical treatment for non-small cell lung cancer emphasizes the importance of proper adjustment when comparing hospitals on outcome indicators.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29625100     DOI: 10.1016/j.athoracsur.2018.02.074

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Lessons learned from the Dutch Institute for Clinical Auditing: the Dutch model for quality assurance in lung cancer treatment.

Authors:  Naomi Beck; Fieke Hoeijmakers; Erwin M Wiegman; Hans J M Smit; Franz M Schramel; Willem H Steup; Ad F T M Verhagen; Wilhelmina H Schreurs; Michel W J M Wouters
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Real-Life Long-Term Cohort of Patients With Stage IIIA Non-Small-Cell Lung Cancer: Overall Survival Related to Patients' Characteristics and Multiple Treatment Models.

Authors:  Fernando Conrado Abrão; Frederico Rafael Moreira; Igor Renato Louro Bruno de Abreu; Marcelo Giovanni Marciano; Riad Naim Younes
Journal:  JCO Glob Oncol       Date:  2021-09

3.  Prognostic factors and patients' profile in treated stage I and II lung adenocarcinoma: a Hospital's Cancer Registry-based analysis.

Authors:  Fernando Conrado Abrão; Stela Verzinhasse Peres; Igor Renato Louro Bruno de Abreu; Riad Naim Younes
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

4.  Development of a data-driven case-mix adjustment model for comparison of hospital performance in hip fracture care.

Authors:  Franka S Würdemann; Arthur K E Elfrink; Janneke A Wilschut; Crispijn L van den Brand; Inger B Schipper; Johannes H Hegeman
Journal:  Arch Osteoporos       Date:  2022-04-27       Impact factor: 2.879

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.